CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
用于 T 细胞的 CRISPR 工具：靶向基因组、表观基因组与转录组
英文原题：CRISPR tools for T cells: targeting the genome, epigenome, and transcriptome.
查看英文原题
CRISPR tools for T cells: targeting the genome, epigenome, and transcriptome.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
T细胞疗法对多种癌症具有治愈潜力。尽管其在血液系统恶性肿瘤中取得了令人瞩目的临床疗效，当前T细胞疗法仍面临应答持久性不足、抗原逃逸、细胞毒性、可及性有限以及实体瘤治疗困难等挑战。CRISPR（成簇规律间隔短回文重复序列）技术的出现为应对这些问题提供了有前景的方案。CRISPR技术已从单纯的基因敲除工具，发展为可在基因组、表观基因组和转录组多个层面工程化改造细胞的先进工具。本综述讨论近期技术进展，以及将其应用于T细胞如何推动下一代细胞疗法的发展。我们着重介绍新兴应用和当前技术局限，并说明未来工具开发旨在克服哪些问题。
展开英文摘要原文
T cell therapy has curative potential for many cancers. Despite impressive clinical efficacy in hematological malignancies, current T cell therapy still faces challenges related to sustaining responses, antigen escape, cytotoxicity, limited accessibility, and difficulties in treating solid tumors. The advent of CRISPR (clustered regularly interspaced short palindromic repeats) technologies provides a promising solution to these challenges.
CRISPR technologies have grown from merely tools for gene knockout to sophisticated tools that can engineer cells at various levels of the genome, epigenome, and transcriptome. In this review we discuss recent technological advancements and how their application to T cells has the potential to steer the next generation of cellular therapy.
We highlight emerging applications and current technological limitations that future tool development aims to overcome.
论文信息
- 作者
- Wachsmann TLA、Qi LS
- 第一作者单位
- Department of Bioengineering, Stanford University, Stanford, CA, USA.United States
- 通讯作者单位
- Department of Bioengineering, Stanford University, Stanford, CA, USA; Sarafan ChEM-H, Stanford University, Stanford, CA, USA; Chan Zuckerberg Biohub - San Francisco, San Francisco, CA, USA. Electronic address: slqi@stanford.edu.United States
- 文献类型
- 综述
- 期刊
- Trends in cancer2025 Oct
- 原文标识
- PubMed 40883169 · DOI 10.1016/j.trecan.2025.08.001
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →